



Point/Counterpoint: Maximizing the Impact of I-O Across NSCLC

Saturday, 7 September 2019 | 14:30–16:00
Vancouver (2003), Hall 8.0, Fira Barcelona, Gran Via
Barcelona, Spain

Meeting Chair



Scott Antonia, MD, PhD
*Duke Cancer Institute
Durham, NC, United States*



**Natasha Leighl, MD, MSc,
FRCPC, FASCO**
*Princess Margaret Cancer Centre
Toronto, Ontario, Canada*



Antonio Calles, MD, MSc
*Hospital General Universitario
Gregorio Marañón
Madrid, Spain*

Debate Topics

Timing of I-O Treatment in Early-Stage NSCLC

Moderator: Natasha Leighl
Scott Antonia vs Antonio Calles

I-O + Chemotherapy vs Non-Chemotherapy I-O Options in 1L mNSCLC

Moderator: Scott Antonia
Antonio Calles vs Natasha Leighl

2L Treatment in an Evolving Landscape: Exploring I-O vs Non-I-O Treatment Options

Moderator: Antonio Calles
Natasha Leighl vs Scott Antonia

Audience Q&A to Follow Presentations

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

This Industry-Sponsored Symposium Is Organized and Funded by the Medical Department of Bristol-Myers Squibb.